Patent ID: 11964011
Assignee: CUREVAC SE
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 0:
1. A polyvalent pharmaceutical composition comprising at least a first purified mRNA and a second purified mRNA formulated in a pharmaceutically acceptable carrier, said first purified mRNA comprising, from 5′ to 3′:
(a) a 5′ cap;
(b) a 5′ untranslated region (UTR);
(c) a first coding sequence encoding a SARS-CoV-2 spike protein at least 90% identical to the amino acid sequence of SEQ ID NO: 10 that is a pre-fusion stabilized spike protein comprising K986P and V987P stabilizing substitutions and a D614G amino acid substitution relative to SEQ ID NO: 10;
(d) a 3′ UTR; and
(e) at least one poly(A) sequence comprising 30 to 200 adenosine nucleotides,, said second purified mRNA comprising a second coding sequence encoding a second viral antigen,, wherein the first and the second purified mRNAs optionally comprise a 1-methylpseudouridine or a pseudouridine nucleotide substitution at one or more uracil position(s).